www.lifescinews.com
Business Products & Services Diagnostics Clinical Research Medical Technology Drug Discovery Research Update
Home Life Science Events       Contact Us
News /Press Release

Eppendorf acquires DASGIP Group

Hamburg/Juelich, 4 January 2012
Eppendorf AG today announced its acquisition of the DASGIP Group, a technology leader in the
fields of bioprocess and information technology. DASGIP, with offices in Juelich, Germany, and
Shrewsbury, Massachusetts, has established a high reputation as developer and manufacturer
of parallel bioreactor systems and innovative control and analysis software.
Eppendorf CEO Dirk Ehlers, Ph.D., commented the transaction: „DASGIP is a strategically
important addition to the Eppendorf Group. DASGIP’s high quality parallel bioreactors and
software solutions nicely complement the current offering of our New Brunswick product lines.
They allow us to forge a comprehensive suite of products for bioprocess research applications,
development and scale up, from 30 mL to 3,000 liters. Furthermore, the advanced software
concepts will position DASGIP as a strong Competence Center in these fields.”
DASGIP CEO Thomas Drescher, Ph.D., added: “The DASGIP and Eppendorf strategies and
corporate cultures have an excellent fit. We look forward to combining our technical expertise
with the broad range of Eppendorf lab solutions in the fields of liquid-, sample- and cell
handling. DASGIP products now can be brought to all major markets worldwide with the
additional sales and service force available through the regional Eppendorf organizations.”
The deal closed on January 2, 2012. Financial terms were not disclosed.
About:
DASGIP is an industry leading supplier of Parallel Bioreactor Systems and Software Solutions for the cultivation of
microbial, plant, animal and human cells. Further information is available at: http://www.dasgip.com
Eppendorf AG, based in Hamburg, Germany, develops, produces and distributes instruments and consumables for
Life Science research and industrial applications. Further information is available at: http://www.eppendorf.com
For further inquiries, please contact:
Dr. Oliver Franz
Eppendorf AG
Barkhausenweg 1
22339 Hamburg
Germany
Phone: + 49 40 53 801 - 801
Fax: + 49 40 53 801 - 835
E-mail: franz.o@eppendorf.de

 

 

 

bio pharma asia
health2 logo
World Vaccine Con 12

 

 
 

 

About Life Sciences Industry News
Subscribe
Advertise
Contribute